Jacobs & Co. CA Sells 1,120 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)


Share on StockTwits

Jacobs & Co. CA lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,564 shares of the biopharmaceutical company’s stock after selling 1,120 shares during the quarter. Jacobs & Co. CA’s holdings in Gilead Sciences were worth $1,781,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Greylin Investment Mangement Inc. lifted its stake in shares of Gilead Sciences by 11.6% during the 4th quarter. Greylin Investment Mangement Inc. now owns 96,969 shares of the biopharmaceutical company’s stock worth $5,649,000 after purchasing an additional 10,103 shares during the last quarter. Monarch Capital Management Inc. lifted its stake in shares of Gilead Sciences by 2.9% during the 4th quarter. Monarch Capital Management Inc. now owns 67,369 shares of the biopharmaceutical company’s stock worth $3,925,000 after purchasing an additional 1,888 shares during the last quarter. Kestra Private Wealth Services LLC lifted its stake in shares of Gilead Sciences by 71.2% during the 4th quarter. Kestra Private Wealth Services LLC now owns 38,271 shares of the biopharmaceutical company’s stock worth $2,168,000 after purchasing an additional 15,917 shares during the last quarter. LS Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 3.1% during the 4th quarter. LS Investment Advisors LLC now owns 61,892 shares of the biopharmaceutical company’s stock worth $3,606,000 after purchasing an additional 1,881 shares during the last quarter. Finally, Kempen Capital Management N.V. lifted its stake in shares of Gilead Sciences by 22.0% during the 4th quarter. Kempen Capital Management N.V. now owns 345,770 shares of the biopharmaceutical company’s stock worth $20,144,000 after purchasing an additional 62,378 shares during the last quarter. 76.36% of the stock is currently owned by institutional investors.

In other news, EVP Brett A. Pletcher sold 1,486 shares of the business’s stock in a transaction dated Thursday, March 11th. The stock was sold at an average price of $63.36, for a total value of $94,152.96. Following the completion of the sale, the executive vice president now directly owns 29,166 shares of the company’s stock, valued at approximately $1,847,957.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 1,975 shares of the business’s stock in a transaction dated Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total value of $133,134.75. Following the completion of the sale, the executive vice president now directly owns 28,832 shares of the company’s stock, valued at $1,943,565.12. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

Shares of NASDAQ GILD traded up $0.13 during trading on Thursday, reaching $65.73. The stock had a trading volume of 99,405 shares, compared to its average volume of 8,691,574. Gilead Sciences, Inc. has a fifty-two week low of $56.56 and a fifty-two week high of $85.79. The company has a debt-to-equity ratio of 1.65, a quick ratio of 3.15 and a current ratio of 3.25. The business’s 50-day moving average price is $64.21 and its 200-day moving average price is $62.46. The company has a market cap of $82.76 billion, a P/E ratio of 67.63, a PEG ratio of 0.67 and a beta of 0.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $2.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.15 by $0.04. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. The business had revenue of $7.42 billion during the quarter, compared to analysts’ expectations of $7.11 billion. Analysts forecast that Gilead Sciences, Inc. will post 7.06 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 30th. Shareholders of record on Monday, March 15th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 4.32%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.68. The ex-dividend date was Friday, March 12th. Gilead Sciences’s payout ratio is 46.25%.

A number of research firms have commented on GILD. BMO Capital Markets decreased their price target on Gilead Sciences from $64.00 to $62.00 and set a “market perform” rating for the company in a research note on Wednesday, December 16th. Morgan Stanley increased their price objective on Gilead Sciences from $83.00 to $87.00 and gave the company an “overweight” rating in a report on Friday, February 5th. Smith Barney Citigroup cut their price objective on Gilead Sciences from $75.00 to $72.00 in a report on Tuesday, December 22nd. TheStreet raised Gilead Sciences from a “c” rating to a “b-” rating in a report on Tuesday, March 30th. Finally, SVB Leerink dropped their target price on Gilead Sciences from $73.00 to $72.00 and set an “outperform” rating on the stock in a report on Thursday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $96.04.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Story: Price Target

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.